NCT04745442

Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Maimónides Biomedical Research Institute of Córdoba · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in patients with confirmed COVID-19 disease and criteria high risk to develop SARS.

Conditions

• Covid19
• Severe Acute Respiratory Syndrome
• Distress Respiratory Syndrome

Interventions

Type	Name	Description
DRUG	Antithrombin + best available treatment	The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
DRUG	Best available treatment	The subject will be treated with the best available treatment for COVID-19.

Timeline

• Start date: 2020-04-27
• Primary completion: 2020-12-20
• Completion: 2021-01-15
• First posted: 2021-02-09
• Last updated: 2021-02-09

Locations

1 site across 1 country: Spain